Randomized Comparison of Olanzapine Versus Risperidone for the Treatment of First-Episode Schizophrenia: 4-Month Outcomes
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders. METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day). RESULTS: Response rates did not significantly differ between olanzapine (43.7%, 95% CI=28.8%-58.6%) and risperidone (54.3%, 95% CI=39.9%-68.7%). Among those responding to treatment, more subjects in the olanzapine group (40.9%, 95% CI=16.8%-65.0%) than in the risperidone group (18.9%, 95% CI=0%-39.2%) had subsequent ratings not meeting response criteria. Negative symptom outcomes and measures of parkinsonism and akathisia did not differ between medications. Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2-1.6) with risperidone and 1.2 (95% CI=1.0-1.4) with olanzapine. Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone. Body mass index at baseline and at 4 months was 24.3 (95% CI=22.8-25.7) versus 28.2 (95% CI=26.7-29.7) with olanzapine and 23.9 (95% CI=22.5-25.3) versus 26.7 (95% CI=25.2-28.2) with risperidone. CONCLUSIONS: Clinical outcomes with risperidone were equal to those with olanzapine, and response may be more stable. Olanzapine may have an advantage for motor side effects. Both medications caused substantial rapid weight gain, but weight gain was greater with olanzapine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Excess mortality of schizophrenia: A meta-analysis
Brown, S. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.171.6.502 · Cited by 869
Bray, G. A., Hollander, P., Klein, S., Kushner, R., Levy, B., Fitchet, M., & Perry, B. H. (2003) · Obesity Research · doi:10.1038/oby.2003.102 · Cited by 344
Safety of Available Agents Used to Treat Bipolar Disorder: Focus on Weight Gain
Nemeroff, C. B. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0506 · Cited by 86
Research works printed but not linked: 24
- 10.1038/sj.npp.1300157 · DOI · Paper page
- 10.1093/oxfordjournals.schbul.a033413 · DOI · Paper page
- 10.1176/appi.ajp.162.5.947 · DOI · Paper page
- 10.1176/appi.ajp.160.8.1396 · DOI · Paper page
- 10.4088/JCP.v64n0913 · DOI · Paper page
- 10.1093/oxfordjournals.schbul.a033476 · DOI
- 10.1093/schbul/sbi032 · DOI
- Lieberman JA, 2005, N Engl J Med, 354, 300
- 10.1016/S0920-9964(98)00105-4 · DOI · Paper page
- 10.1097/01.jcp.0000130558.86125.5b · DOI · Paper page
- 10.1097/00004714-199710000-00010 · DOI · Paper page
- 10.1176/appi.ajp.158.5.765 · DOI · Paper page
- 10.1097/00019442-200311000-00008 · DOI
- 10.1056/NEJMe058200 · DOI
- 10.1176/appi.ps.52.7.967 · DOI · Paper page
- 10.4088/JCP.v62n0208 · DOI
- 10.1089/104454602760386941 · DOI
- 10.1176/appi.ajp.159.4.655 · DOI · Paper page
- 10.1056/NEJMra012586 · DOI · Paper page
- 10.1176/appi.ps.54.8.1155 · DOI · Paper page
- 10.3109/10401230309085669 · doi:10.3109/10401230309085669
- 10.1001/archinte.160.7.898 · DOI · Paper page
- American Diabetes Association, 2001, Diabetes Care, 24, S5, 10.2337/diacare.24.1.5 · DOI · Paper page
- 10.1056/NEJMoa021423 · DOI · Paper page
Cited by
Correll, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Goldberg, T. E., Goldman, R. S., Burdick, K. E., Malhotra, A. K., Lencz, T., Patel, R. C., Woerner, M. G., Schooler, N. R., Kane, J. M., & Robinson, D. G. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1115 · Cited by 394
Self-citation
Metadata
- Authors
- Robinson, D. G., Woerner, M. G., Napolitano, B., Patel, R. C., Sevy, S. M., Gunduz-Bruce, H., Soto-Perello, J. M., Mendelowitz, A., Khadivi, A., Miller, R., McCormack, J., Lorell, B. S., Lesser, M. L., Schooler, N. R., & Kane, J. M.
- Venue
- American Journal of Psychiatry
- Published
- 2006-12
- Volume
- 163
- Issue
- 12
- Pages
- 2096-2102
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2107920654
- Cited by
- 107
- References
- 4
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.